No Data
Biodexa Pharmaceuticals Announces Allowance of U.S. Patent Covering ERapa
Express News | Biodexa Announces Upcoming Issuance Of U.S. Patent For Oral Rapamycin Nanoparticle Preparations
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Biodexa Pharmaceuticals Shares Are Trading Higher After the Company Received Fast Track Status From the FDA for ERap.
Biodexa Wins FDA Fast Track for ERapa, Targets Familial Adenomatous Polyposis Treatment
Can’t Trade 4Shit : My friend, you are not alone